Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin αvβ6 and secreting anti-PD-L1 scFv
Open Access
- 16 April 2025
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-17
Abstract
Cholangiocarcinoma (CCA) is a fatal bile duct cancer with high resistance and recurrence rates, with only one fifth of patients eligible for surgical treatment. The disease resists standard chemotherapy and often relapses. Chimeric antigen receptor (CAR) T cell therapy has shown promise for hematological malignancies but faces challenges in solid tumors due to resistance mechanisms like PD-L1 expression, which tumors use to evade the immune system. To address this challenge, we developed fifth-generation CAR T cells targeting integrin αvβ6 that also secrete anti-PD-L1 single-chain variable fragment (scFv) to target both tumor cells and the PD-1/PD-L1 pathway. We examined integrin αvβ6 and PD-L1 expression in CCA cell lines and engineered T cells to express either fourth-generation CAR T cells targeting integrin αvβ6 (A20 CAR4 T cells) or fifth-generation CAR T cells with anti-PD-L1 scFv secretion (A20 CAR5 T cells). In vitro, A20 CAR5 T cells exhibited less exhaustion and superior long-term functionality compared to A20 CAR4 T cells. In 3D spheroid models of CCA, A20 CAR5 T cells demonstrated enhanced antitumor activity and better infiltration into the spheroid core. These findings suggest that A20 CAR5 T cells have significant potential and warrant further in vivo studies and clinical trials.Keywords
All Related Versions
Funding Information
- Faculty of Medicine Siriraj Hospital, Mahidol University (R016334002, R016737004)
- Mahidol University
This publication has 42 references indexed in Scilit:
- Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancerPancreatology, 2024
- Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myelomaBiomedicine & Pharmacotherapy, 2023
- Immune checkpoint therapy for solid tumours: clinical dilemmas and future trendsSignal Transduction and Targeted Therapy, 2023
- Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibitionInternational Immunopharmacology, 2022
- Integrin αvβ6 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinomaPathology - Research and Practice, 2020
- The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapyThe Journal of Pathology, 2019
- Expression of checkpoint molecules on myeloid-derived suppressor cellsImmunology Letters, 2017
- Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancerBritish Journal of Cancer, 2015
- 3D Cell Culture Systems: Advantages and ApplicationsJournal of Cellular Physiology, 2014
- CholangiocarcinomaThe Lancet, 2005